Article
Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition.
Circulation research - 18 Oct 2002
Hahn Harvey S, Yussman Martin G, Toyokawa Tsuyoshi, Marreez Yehia, Barrett Thomas J, Hilty K Chad, Osinska Hanna, Robbins Jeffrey, Dorn Gerald W
Abstract excerpt
To delineate the in vivo cardiac functions requiring normal delta protein kinase C (PKC) activity, we pursued loss-of-function through transgenic expression of a deltaPKC-specific translocation inhibitor protein fragment, deltaV1, in mouse hearts. Initial results using the mouse alpha-myosin heavy chain (alphaMHC) promoter resulted in a lethal heart failure phenotype. Viable deltaV1 mice were therefore obtained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
